NAD + - and EVA1-C-dependent reversal of neurological deficits is mediated by differential alternative RNA splicing in tauopathic animal models

Ruixue Ai, Lingyan Mao, Xurui Jin, Shiqi Zhang, J. Pan, Mariá José Lagartos-Donate, Shuqin Cao, Guang Yang, Chenglong Xie, Xiongbin Kang, Pingjie Wang, Yang Hu, Linda H. Bergersen, Jon Storm‐Mathisen, Hidehito Kuroyanagi, Beatriz Escobar-Doncel, N. González, Farrukh A. Chaudhry, Zeyuan Wang, Qiang Zhang, Zhangming Niu, Guobing Chen, Oscar Junhong Luo, Evandro Fei FangbioRxiv 2024 · DOI

TL;DR

This study reveals that NAD+ (specifically via Nicotinamide Riboside, NR) can reverse neurological deficits in tauopathy models by modulating alternative RNA splicing (ASEs), particularly affecting the EVA1-C gene. This work highlights ASEs as a key mechanism through which NAD+ exerts its beneficial effects and suggests novel therapeutic avenues for Alzheimer's Disease (AD).

What Problem Does This Paper Address?

Alzheimer's Disease (AD) is a devastating neurodegenerative disorder with limited effective treatments. While NAD+ and its precursors show promise in slowing AD progression, the underlying molecular mechanisms, especially concerning RNA splicing, remain unclear. Aberrant alternative splicing (ASEs) is increasingly recognized as an aging hallmark and a contributor to AD pathology. This paper aims to bridge this gap by investigating how NAD+ influences ASEs in tauopathy models and how these changes impact disease progression, with a specific focus on the EVA1-C gene.

Methods

The researchers employed a multi-faceted approach:

  • Transcriptomic Analysis: RNA-sequencing (RNA-seq) was performed on mouse brains (hTau.P301S transgenic mice and wild-type controls) and C. elegans models, both with and without NR treatment, to identify differentially expressed genes and ASEs.
  • AI-based Prediction: Deep learning algorithms were used to predict EVA1-C protein structures and protein-protein interactions (PPIs). This included leveraging a novel "PromptProtein" model for enhanced prediction accuracy.
  • Experimental Validation: Findings from transcriptomic and AI analyses were validated using various experimental models:
  • Cell Culture: Human neuroblastoma SH-SY5Y cells overexpressing tau were used to study EVA1-C protein levels and interactions.
  • C. elegans Models: Transgenic worms expressing tauopathy-like pathology were used to assess the impact of NR and EVA1-C knockdown on memory and lifespan.
  • Mouse Models: hTau.P301S mice were used to study the effects of NR on behavior and gene expression.
  • Post-mortem Human Brain Tissue: Hippocampal and entorhinal cortex samples from AD patients at different Braak stages were analyzed for EVA1-C expression.
  • Protein Docking and Molecular Dynamics: Simulations were conducted to estimate binding modes and energetics between EVA1-C isoforms and potential interacting partners like HSP70 and BAG-1.

Datasets

  • Mouse RNA-seq Data: Hippocampal RNA-seq data from 14-month-old wild-type (WT) and hTau.P301S mice, treated with or without Nicotinamide Riboside (NR), were utilized.
  • C. elegans RNA-seq Data: Data from C. elegans models were used to study aging and tau pathology effects on RNA splicing.
  • Human Brain Tissue Data: Post-mortem hippocampal and entorhinal cortex samples from AD patients and age-matched healthy controls were analyzed.
  • Public Databases: The STRING database and the AlphaFold Protein Structure Database were used for AI model training and protein structure prediction.

Key Insights and Ideas

  • NAD+ as a Splicing Modulator: The study strongly suggests that NAD+ (via NR) isn't just a metabolic booster but actively influences RNA splicing, particularly in the context of neurodegenerative diseases. This opens up a new dimension to understanding NAD+'s therapeutic potential.
  • EVA1-C as a Key Player: The EVA1-C gene and its isoforms emerge as a critical target. Its expression is dysregulated in tauopathy and AD, and its modulation by NR appears central to the observed neurological benefits.
  • ASEs as a Disease Hallmark: The research reinforces the idea that aberrant alternative splicing is not just a consequence but potentially a driver of tauopathy and AD, making it a promising therapeutic target.
  • AI for PPI Prediction: The application of advanced AI models (like PromptProtein) for predicting protein-protein interactions, especially considering 3D structures, represents a significant step forward in understanding complex molecular mechanisms.

Key Results

  • NR Reverses Neurological Deficits: NR treatment improved memory and extended lifespan in tauopathic C. elegans models, and these benefits were abrogated when EVA1-C was knocked down, highlighting EVA1-C's crucial role.
  • EVA1-C Downregulation in AD: EVA1-C protein levels were significantly reduced in neurons of AD patients across different Braak stages, particularly in the entorhinal cortex and hippocampus.
  • NR Modulates EVA1-C Splicing: In tauopathic mice, NR treatment led to differential expression and splicing of EVA1-C isoforms, with some isoforms showing higher affinity for HSP70.
  • Widespread ASE Dysregulation: Transcriptomic analysis revealed significant dysregulation of various ASE subtypes (MES, IR, ES) in tauopathic models, with NR treatment showing a normalizing effect.
  • AI Predicts Key Interactions: AI-driven PPI prediction identified HSP70 and BAG-1 as likely interaction partners for EVA1-C, with subsequent experimental validation supporting these findings.

Limitations and Future Work

  • EVA1-C Isoform-Specific Antibodies: The authors acknowledge the lack of EVA1-C isoform-specific antibodies, which limited the use of direct immunological approaches for validation. They compensated with AI-based deep learning.
  • Bulk RNA-seq Limitations: The use of bulk RNA-seq data means that expression values are averaged across different cell types, potentially masking cell-type-specific effects.
  • Further Investigation of PPIs: While AI and docking simulations identified potential interactions between EVA1-C, HSP70, and BAG-1, further experimental verification of these specific isoform-protein interactions is warranted.
  • Therapeutic Development: The study suggests that developing splice-switching therapeutics targeting NAD+-regulated ASEs, particularly those involving EVA1-C, could be a promising avenue for AD treatment. Future work could focus on optimizing these strategies.

Summary updated

Abstract

Abstract Aberrant alternative splicing (ASEs) is an aging hallmark to Alzheimer’s Disease (AD). Although NAD + and related metabolites can slow down AD, NAD + on ASEs in AD remain unclear. Mouse transcriptomic data revealed NR-induced ASEs, focusing on the Eva1-C locus. AI-based algorithms predicted EVA1-C protein structures and protein-protein interactions. AD postmortem brain samples and tauopathy models including transgenic mice and worm was used for validation. NAD + abundance/metabolic status modulates ASEs and the expression of EVA1-C isoforms, which in turn regulate the interaction with BAG-1 and HSP70 proteins. Importantly, EVA1-C is dramatically reduced in 20 Braak 5/6 AD patients compared to cognitive normal humans in different brain regions. NAD + metabolism modulates abundance of specific mRNA isoforms, and that ASEs influence disease progression in model tauopathies and potentially AD. These results could facilitate future development of NAD + -based splice-switching therapeutics for AD. Teaser Unveiling the Link Between NAD + Metabolism and Alzheimer’s Disease: Discovering the Role of Alternative RNA Splicing in Disease Progression and Potential Therapeutic Targets
BibTeX
@misc{ai2024nad,
  author = {Ruixue Ai and Lingyan Mao and Xurui Jin and Shiqi Zhang and J. Pan and Mariá José Lagartos-Donate and Shuqin Cao and Guang Yang and Chenglong Xie and Xiongbin Kang and Pingjie Wang and Yang Hu and Linda H. Bergersen and Jon Storm‐Mathisen and Hidehito Kuroyanagi and Beatriz Escobar-Doncel and N. González and Farrukh A. Chaudhry and Zeyuan Wang and Qiang Zhang and Zhangming Niu and Guobing Chen and Oscar Junhong Luo and Evandro Fei Fang},
  title = {{NAD <sup>+</sup> - and EVA1-C-dependent reversal of neurological deficits is mediated by differential alternative RNA splicing in tauopathic animal models}},
  year = {2024},
  doi = {10.1101/2024.10.27.620478},
  howpublished = {bioRxiv},
}
Figure